Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Testosterone Clear all
Active, not recruiting Phase 3 Interventional

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy

NCT04455750
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Enzalutamide, Rucaparib camsylate, Placebo, Leuprolide Acetate, Goserelin Acetate, Degarelix, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
414
States / cities
Anchorage, Alaska • Phoenix, Arizona • Hot Springs, Arkansas + 298 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

An Open-Label Study of 50 Mg Oral Testosterone Undecanoate (Kyztrex) in Menopausal Women with Low Testosterone and HSDD

NCT06082817
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Oral Testosterone Undecanoate
Drug
Lead sponsor
San Diego Sexual Medicine
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

Testosterone Antidepressant Augmentation in Women

NCT01783574
View directory record Official record
Conditions
Depression
Interventions
Testosterone, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 9, 2026, 9:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Diurnal Testosterone Concentration

NCT03091296
View directory record Official record
Conditions
Testosterone Deficiency
Interventions
Not listed
Lead sponsor
Men's Health Boston
Other
Eligibility
18 Years to 46 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 26, 2018 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

TRADE-Testosterone Replacement and Dutasteride Effectiveness

NCT00194675
View directory record Official record
Conditions
Hypogonadism, Benign Prostatic Hyperplasia
Interventions
Dutasteride, Testosterone gel, Placebo dutasteride
Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 9, 2026, 9:06 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers

NCT05669664
View directory record Official record
Conditions
Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darolutamide, Leuprolide Acetate, Magnetic Resonance Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
27
States / cities
Irvine, California • Los Angeles, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Recruiting Not applicable Interventional

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

NCT00588185
View directory record Official record
Conditions
Prostate Cancer
Interventions
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Male only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

Assessing the Safety/Efficacy of Transdermal Testosterone in Female Patients With Symptomatic Heart Failure

NCT00957034
View directory record Official record
Conditions
Heart Failure
Interventions
placebo, testosterone
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
50 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
16
States / cities
Phoenix, Arizona • Tucson, Arizona • Lakewood, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2012 · Synced Sep 9, 2026, 9:06 AM EDT
Active, not recruiting Not applicable Interventional

Evaluating the Influence of Diet-induced Weight Loss on Fat (Adipose) Tissue's Insulin Sensitivity and Testosterone Synthesis in Women With Overweight or Obesity, Insulin Resistance, and Hyperandrogenemia

NCT06998238
View directory record Official record
Conditions
Overweight and Obesity, Hyperandrogenemia, Insulin Resistance
Interventions
Mediterranean-based, carbohydrate restricted, calorie reduced diet
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 3 Interventional

A Randomized, Double Blind, Placebo-Controlled, Multi-Center Phase III Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Testosterone and Sperm Concentration Following Treatment With 12.5 mg or 25 mg Androxal or AndroGel 1.62%

NCT01993225
View directory record Official record
Conditions
Secondary Hypogonadism
Interventions
Androxal 12.5 mg/25 mg, Placebo Capsules, AndroGel 1.62%, Placebo Gel
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 60 Years · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
9
States / cities
Birmingham, Alabama • Mobile, Alabama • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate Serum Testosterone Levels in Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02737332
View directory record Official record
Conditions
Prostate Cancer
Interventions
Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate)
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2021 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Results available

Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism

NCT03887936
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypogonadism
Interventions
Testosterone gel 1.62%, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 70 Years · Male only
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Completed No phase listed Observational

Long-term Lifestyle Change and Testosterone Replacement

NCT03256292
View directory record Official record
Conditions
Hypogonadism, Aging, Overweight and Obesity
Interventions
Testosterone replacement, lifestyle
Drug · Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
65 Years to 85 Years · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle

NCT00586898
View directory record Official record
Conditions
Prostate, Cancer, Hormonal Cycling
Interventions
GnRH, Ketoconazole, Bicalutamide, Testosterone transdermal gel, Estrogen transdermal patch
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Sep 9, 2026, 9:06 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

NCT00467987
View directory record Official record
Conditions
Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
Interventions
androgel, placebo
Drug
Lead sponsor
University at Buffalo
Other
Eligibility
31 Years to 60 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

NCT04467697
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
SOV2012-F1
Drug
Lead sponsor
Marius Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
19
States / cities
Birmingham, Alabama • Mobile, Alabama • Aventura, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2024 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men

NCT00957801
View directory record Official record
Conditions
Sarcopenia
Interventions
Testosterone injection, Testosterone gel, Medrol
Drug
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
60 Years to 85 Years · Male only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 9, 2026, 9:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Adolescent Mood During Puberty and Testosterone

NCT06072677
View directory record Official record
Conditions
Adolescent Depression
Interventions
Healthy Minds Program
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
11 Years to 14 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2026 · Synced Sep 9, 2026, 9:06 AM EDT
Not listed Not applicable Interventional

Randomized Study of Testosterone and Progressive Resistance Exercise in Men With Burn Injury

NCT00006129
View directory record Official record
Conditions
Burns
Interventions
testosterone
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 50 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 9, 2026, 9:06 AM EDT
Withdrawn Phase 4 Interventional

Effect of Testosterone Gel Replacement on Fat Mass in Males With Low Testosterone Levels and Diabetes

NCT00440440
View directory record Official record
Conditions
Hypogonadism, Diabetes
Interventions
Testosterone gel, placebo
Drug
Lead sponsor
Diabetes Center of the Southwest
Other
Eligibility
35 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Midland, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 1 Interventional

Study of the Safety, Tolerability and Pharmacokinetics of Testosterone Undecanoate in Hypogonadal Males.

NCT01346319
View directory record Official record
Conditions
Hypogonadal Males
Interventions
ABT-SLV361, placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 80 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2011 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Phase II Randomized Study of Physiologic Testosterone Replacement in Premenopausal, HIV-Positive Women

NCT00004400
View directory record Official record
Conditions
HIV Infections, Cachexia
Interventions
testosterone
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
3
States / cities
Los Angeles, California • Torrance, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Results available

Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men

NCT03868059
View directory record Official record
Conditions
Hypogonadism, Male
Interventions
LPCN 1021
Drug
Lead sponsor
Lipocine Inc.
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Aventura, Florida • Coral Gables, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Sep 9, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism

NCT02777242
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone enanthate auto-injector
Combination Product
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Birmingham, Alabama • New York, New York • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2018 · Synced Sep 9, 2026, 9:06 AM EDT